Research Article

The Role of Highly Active Antiretroviral Therapy (HAART) on Interleukin 17A (IL-17A) in Normotensive and Preeclamptic Black South African Women

Wendy N. Phoswa, Thajasvarie Naicker, Veron Ramsuran, and Jagidesa Moodley

1Discipline of Obstetrics and Gynecology, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
2Optics and Imaging Centre, University of KwaZulu-Natal, Durban, South Africa
3KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
4Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
5Women’s Health and HIV Research Group, University of KwaZulu-Natal, Durban, South Africa

Correspondence should be addressed to Wendy N. Phoswa; phoswawendy@gmail.com

Received 2 February 2020; Revised 27 April 2020; Accepted 1 May 2020; Published 30 May 2020

Academic Editor: Susan Cu-Uvin

Copyright © 2020 Wendy N. Phoswa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Interleukin 17A has been implicated in the pathophysiology of both human immune deficiency virus and preeclampsia. This study evaluated serum levels of IL-17A based on pregnancy type, gestational age, HIV status, and duration of HAART.

Material and Methods. A sample size of 250 was analysed: normotensives (n = 150; N) and preeclamptics (n = 100; PE). Normotensives were further stratified into HIV negative (n = 90), HAART-acute (n = 30), and HAART-chronic (n = 30). The PE group was divided into early onset (n = 50; EOPE) and late onset (n = 50; LOPE). The EOPE and LOPE groups were subdivided into HIV negative (n = 30), HAART-acute (n = 10), and HAART-chronic (n = 10). Analysis of IL-17A was performed using a multiple Bio-Plex immunoassay method.

Results. Pregnancy type: the levels of IL-17A were increased in PE compared to N (P = 0.0014). Gestational age: the levels of IL-17A were increased in EOPE compared to N group (P = 0.0113). A significant increase in the levels of IL-17A in LOPE compared to N was observed (P = 0.0063). HIV status: the levels of IL-17A were increased in PE compared to N (P = 0.0114) and in EOPE compared to N groups (P = 0.0071). HAART duration: the concentration of IL-17A was increased in HAART-chronic PE compared to N groups (P = 0.0062). There was also an increase in the levels of IL-17A in EOPE compared to N (P = 0.0029).

Conclusion. The study demonstrates that IL-17A is involved in the pathophysiology of PE and that in the presence of HIV infection, chronic HAART administration predisposes women to the development of EOPE.

1. Introduction

Preeclampsia (PE) is a pregnancy-specific, multisystemic disorder that occurs in 2-8% of all pregnancies worldwide [1]. Preeclampsia usually presents with the clinical signs of new-onset hypertension after 20 weeks of gestation [2, 3]. Currently, there is no cure for PE with the only effective resolution being delivery, and even then, PE may continue in the postpartum period or present de novo. Furthermore, women with PE as well as their children are at a greater risk of developing chronic diseases including cardiovascular diseases in later life [4]. Nonetheless, much progress has been made in the understanding of the pathophysiology of PE; abnormal placent development characterized by inadequate spiral artery remodelling maybe the primary factor that leads to pathogenesis of the disease. This lack of physiological conversion of the spiral artery leads to a decreased utero-placental blood flow. In response to hypoxia, the placenta releases various substances including trophoblastic debris and apoptotic cells. These substances cause an imbalance
between angiogenic and antiangiogenic factors which contribute to widespread endotheliosis leading to vasospasm, hypertension, and multiple organ affection [2, 4].

Environmental, genetic, and immunological factors may initiate/exacerbate the cascade of events that lead to placental dysfunction. In addition, the frequency of PE may be affected by HIV infection. Both PE and HIV infection are currently the leading causes of maternal and fetal deaths in sub-Saharan countries [5, 6].

The current recommended treatment for HIV infection is highly active antiretroviral therapy (HAART) [4]. However, HAART may alter the immune response of HIV-infected pregnant women thereby predisposing them to the development of PE [4]. Nonetheless, inflammatory cytokines (pro- and anti-inflammatory) play a vital role in the pathophysiology of both conditions.

During the pathophysiology of PE, there is a shift from anti-inflammatory (Th2) to a proinflammatory response (Th1) with an elevation of IL-2, IL-6, IL-12, IFN-γ, and TNF-α. Several studies have found increased levels of these cytokines in PE [7–11]. During HIV infection, there is a shift from Th1 to Th2 immune response. However, this shift is counteracted by HAART [12]. Studies have documented that HIV-infected women have a higher risk of the development of PE compared to HIV-naive women, postulated to emanate from the immune reconstitution effects of HAART [13–15].

Since both PE and HIV are immune/inflammatory conditions, exaggerated activation or reduction of Th1/Th2 cytokines has been reported by several studies to be strongly associated with the pathophysiology of these disorders [7, 16–18]. Amongst these cytokines, the role of IL-17 in the pathophysiology of both conditions still remains controversial; no studies have been reported on the role of IL-17A in HIV-infected women who develop PE.

Interleukin IL-17A is a proinflammatory cytokine involved in the pathophysiology of both PE and HIV infection. Increased concentrations of IL-17A have been shown to be responsible for the activation of inflammatory responses in PE [19, 20]. In addition, IL-17A has been associated with the development of PE through induction of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-8 [21]. In contrast, a study by Wu et al. suggested a beneficial function for IL-17A during pregnancy including the promotion of embryo implantation and maintenance of pregnancy [22]. Additionally, during the progression of HIV infection, IL-17A declines in both human and animal models [23]. However, long-term HAART exposure leads to IL-17A restoration [23].

This novel study focused on the role of HAART on Th17 (IL-17A) in a homogenous population of pregnant normotensive and preeclamptic women, by comparing the serum concentrations of these cytokines in both study groups. This study may contribute to a better understanding of Th17 expression in the duality of HIV-associated normotensive and PE HAART-naïve (acute) and HAART-experienced (chronic) women.

2. Materials and Methods

2.1. Study Population and Sample Collection. Institutional ethical and hospital regulatory permissions were obtained for the study (Biomedical Research Ethics Committee, University of KwaZulu-Natal, South Africa (BCA338/17). After written consent was obtained, preeclamptic (PE) and normotensive (N) HIV-positive and HIV-negative Black South African pregnant women were recruited at a public health care hospital in South Africa. Normotensive (n = 90, age range: 18 ± 41 years) and PE (n = 96, age range: 18 ± 44 years) patients were recruited. Preeclampsia was defined as new-onset blood pressure of ≥140/90 mmHg taken on two occasions 4 hours apart and at least 1+ proteinuria measured by a urinary dipstick. Normotensive pregnant participants were defined as those with a blood pressure of ≤120/80 mmHg and without evidence of proteinuria. The relevant data of all research participants were obtained from their maternity case records. HIV testing was done after counselling using a rapid point-of-care test kit initially, as is the standard of care in South Africa. Maternal weight was categorised as normal weight (BMI: 18-25 kg/m²), overweight (BMI: 25-30 kg/m²), and obese (BMI: >30 kg/m²).

To maintain ethnographic and anthropometric consistency, all patients recruited were of African ancestry and residents in the same geographical location. All participants were nonsmokers and nonconsumers of alcohol or recreational drugs, and all HIV-infected participants were on highly active antiretroviral therapy (HAART: tenofovir, emtricitabine, and efavirenz) as per South African National HIV guidelines [11]. HAART is the current recommended treatment for HIV infection. The current recommended treatment for HIV infection in pregnant and nonpregnant women is HAART [24]. The use of HAART in pregnancy is important for the reduction of perinatal transmission by several mechanisms, including lowering maternal antepartum viral load and preexposure and postexposure prophylaxis of the infant [25]. Women with chronic medical conditions were excluded from the study.

For analysis, women were grouped according to pregnancy type, gestational age, and HIV status. Women with PE were grouped into early onset, that is, ≤33 weeks + 6 days (n = 50; EOPE), and late onset ≥34 weeks of gestation (n = 50; LOPE).

The EOPE and LOPE groups were, respectively, subvided by HIV status and duration of ARV therapy into HIV negative (n = 30), HIV acute (n = 10), and HIV chronic (n = 10). Similarly, the normotensive group was subdivided according to HIV status and duration of ARV therapy into HIV negative (n = 90), HIV positive acute (n = 30), and HIV positive chronic (n = 30).

HIV positive acute was defined as women who were on HAART treatment for the first time during pregnancy, and HIV positive chronic were defined as women who were previously on HAART before pregnancy.

2.2. Quantification of Human Cytokine Interleukin 17A (IL-17A). Maternal blood samples collected in sterile serum separation tubes (Clot Activator: BD VAC PL PLAIN 6ML PE: 366815: Becton Dickinson) were centrifuged at 3000 rpm for 10 min at 4°C, and the supernatant was used for the quantification of Th1 (IL-2, IL-6, IL-12, IL-17, IFN-γ, and TNF-α), Th2 (IL-4, IL-5, IL-10, and IL-13), and
Table 1: Patient demographic features of the study groups (normotensive = 150, early-onset preeclampsia = 50, and late-onset preeclampsia = 50).

| Variables                  | Groups   | Median   | Q1-Q3     | Mean ± SD   | P value |
|----------------------------|----------|----------|-----------|-------------|---------|
| Maternal weight (kg)       | N        | 77       | 65-100    | 81.92 ± 18.35| 0.1316  |
|                            | EOPE     | 79       | 67.50-100.5| 86.85 ± 30.31|         |
|                            | LOPE     | 96.50    | 72.50-113.0| 93.15 ± 21.95|         |
| Maternal height (m)        | N        | 157      | 153.25-163| 157.5 ± 7.242|         |
|                            | EOPE     | 159      | 154.5-164 | 158.8 ± 7.967| 0.6761  |
|                            | LOPE     | 160      | 155-164   | 159.1 ± 6.934|         |
| BMI (kg/m²)                | N        | 32.05    | 25.72-38.65| 32.59 ± 7.301| 0.0638  |
|                            | EOPE     | 31.64    | 25.80-39.78| 33.52 ± 9.483|         |
|                            | LOPE     | 38       | 32.93-41.50| 37.20 ± 8.021|         |
| Systolic blood pressure (mmHg) | N      | 109      | 98.25-113.75| 108.0 ± 11.25|         |
|                            | EOPE     | 146      | 144-157   | 149.9 ± 10.17| ***<0.0001|
|                            | LOPE     | 145      | 140-149.75| 145.40 ± 7.35|         |
| Diastolic blood pressure (mmHg) | N     | 65.5     | 61-72     | 65.52 ± 9.38 |         |
|                            | EOPE     | 95       | 90-104    | 96.70 ± 9.20 | ***<0.0001|
|                            | LOPE     | 94       | 90-98     | 93.25 ± 5.87 |         |
| Gestational age (weeks)    | N        | 35       | 26-38     | 31.88 ± 6.73 | ***<0.0001|
|                            | EOPE     | 24       | 20-30     | 24.25 ± 5.77 |         |
|                            | LOPE     | 36       | 35-37.25  | 35.95 ± 1.96 |         |
| Maternal age (years)       | N        | 28       | 25-32.75  | 28.60 ± 5.90 |         |
|                            | EOPE     | 28.5     | 22.75-34.25| 28.19 ± 7.35| 0.9574  |
|                            | LOPE     | 29       | 24-32.5   | 28.45 ± 7.13 |         |

N: normotensive; EOPE: early-onset preeclampsia; LOPE: late-onset preeclampsia.

3. Statistical Analysis

GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, California, USA) was used to analyse the data. When the distribution was parametric, descriptive statistics for continuous data is presented by median, interquartile range (IQR), and mean ± standard deviation, whilst nonparametrically distributed data are presented as median and IQR. To determine statistical significance across all groups, a Mann–Whitney U or Kruskal-Wallis test in combination with Dunn’s multiple comparison post hoc test was carried out. Statistical significance was P < 0.05.

4. Results

4.1. Clinical Characteristics of Participants. Table 1 provides a summary of the clinical and demographic features of the study population. As expected, systolic and diastolic blood pressures (BP) differed between the normotensive and PE groups (P ≤ 0.0001). Similarly, gestational age was statistically different between the normotensive pregnant and PE groups (P < 0.001 each; two-sample Wilcoxon rank-sum (Mann–Whitney) test). There were no significant differences in maternal weight (P = 0.1316), maternal height (P = 0.6761), BMI (P = 0.0638), and maternal age (P = 0.9574) between normotensive versus EOPE versus LOPE groups.

4.2. Serum Concentration Levels of IL-17A. These analytes were below the detection limits: Th1 (IL-2, IL-6, IL-12, IFN-γ, and TNF-α) and Th2 (IL-4, IL-5, IL-10, and IL-13).
4.2.1. Pregnancy Type. The concentration of IL-17A was statistically different between the N and PE groups (Mann–Whitney $U = 881.5; P = 0.0014$) Figure 1. The concentration of IL-17A was decreased in the N ($mean = 4.228 \text{ pg/ml}; 95\% CI: 4.576–3.881$) compared to the PE group ($mean = 5.468 \text{ pg/ml}; 95\% CI: 6.332–4.604$).

4.2.2. Gestational Age. The concentration of IL-17A was statistically different between N and EOPE (Mann–Whitney $U = 567.5; P = 0.0113$) Figure 2. There is a decrease in the concentration of IL-17A in the N group ($mean = 4.243 \text{ pg/ml}; 95\% CI: 4.605–3.881$) compared to the EOPE group ($mean = 5.468 \text{ pg/ml}; 95\% CI: 6.332–4.604$). Additionally, there was a significant difference in the levels of IL-17A between N and LOPE groups (Mann–Whitney $U = 314.0; P = 0.0063$) Figure 2. A decrease in the levels of IL-17A in N ($mean = 4.205 \text{ pg/ml}; 95\% CI: 4.943–3.466$) compared to the LOPE ($mean = 5.468 \text{ pg/ml}; 95\% CI: 6.332–4.604$) was observed. Furthermore, there was no significant difference in the levels of IL-17A between EOPE and LOPE (Mann–Whitney $U = 333.0; P = 0.3341$) Figure 2.

4.3. HIV Status

4.3.1. HIV Negative. No statistically significant effect was observed in IL-17A concentration between N and PE (Mann–Whitney $U = 194.5; P = 0.1014$) Figure 3. There is no statistical difference observed in IL-17 concentration between the N and EOPE groups (Mann–Whitney $U = 103.5; P = 0.3266$) Figure 3. A downward trend in IL-17A concentration was observed in the N group ($mean = 3.967 \text{ pg/ml}; 95\% CI: 4.336–3.597$) compared to the EOPE group ($mean = 4.735 \text{ pg/ml}; 95\% CI: 5.748–3.723$).
### 4.3.2. HIV Positive.

A significant effect was observed in IL-17A concentration between HIV positive N and PE (Mann–Whitney U = 127.5; P = 0.0114) Figure 4. A downward trend in IL-17A concentration was observed in the N group (mean = 4.639 pg/ml, 95% CI: 5.516–3.762).

A significant difference was also noted in N vs. EOPE (Mann–Whitney U = 137.5; P = 0.0071) Figure 4. A decrease in IL-17A concentration was noted in N (mean = 4.450 pg/ml, 95% CI: 5.033–3.867) compared to EOPE (mean = 6.220 pg/ml, 95% CI: 7.679–4.761). Additionally, there was no statistically significant difference between N and LOPE (Mann–Whitney U = 88.00; P = 0.6724) Figure 4.

There was no statistically significant change in the concentration of IL-17A between EOPE and LOPE (Mann–Whitney U = 48.00; P = 0.4355) Figure 4.

#### 4.4. Duration of HAART

**4.4.1. HAART-Acute.** There was no statistical difference in IL-17A between N and PE groups (Mann–Whitney U = 69.5; P = 0.9256) Figure 5. Similarly, IL-17A concentration did not differ between N and EOPE women (Mann–Whitney U = 47.00; P = 0.3662) Figure 5. Nonetheless, a downward trend in IL-17A concentration was observed in N (mean = 4.462 pg/ml, 95% CI: 5.265–3.658) compared to EOPE (mean = 4.813 pg/ml; 95% CI: 6.259–3.366) groups. Likewise, there was no statistical difference observed in IL-17A concentration between N and LOPE (Mann–Whitney U = 17.00; P = 0.3886) Figure 5. Despite the nonsignificance, a downward trend in IL-17 concentration was observed between N (mean = 4.462 pg/ml, 95% CI: 5.265–3.658) and LOPE (mean = 4.667 pg/ml; 95% CI: 7.535–1.798) groups. No statistically significant effect was observed in IL-17A concentration between HIV acute EOPE and LOPE (Mann–Whitney U = 11.50; P = 0.5000) Figure 5.

**4.4.2. HAART-Chronic.** The concentration of IL-17A was statistically different between the pregnancy types (N vs. PE groups) (Mann–Whitney U = 71.00; P = 0.0062) Figure 6. There was a decrease in the concentration of IL-17A in the N group (mean = 4.633 pg/ml; 95% CI: 5.682–3.584)

---

**Figure 3:** Serum concentration levels of IL-17 (pg/ml) according to HIV status. 
*HIV-negative groups:* (a) HIV-negative normotensive (N-) vs. HIV-negative preeclamptic (PE-); (b) N- vs. EOPE-; (c) N- vs. LOPE-; (d) EOPE- vs. LOPE-. Results are represented as median and interquartile range. No significant difference in serum concentration levels between N- vs. PE-, N- vs. EOPE-, and EOPE- vs. LOPE-. *Serum concentration levels are significantly different between N- and LOPE-, *P* = 0.0429.

| Groups          | Normotensive | Preeclamptic | Early-onset preeclamptic | Late-onset preeclamptic |
|-----------------|--------------|--------------|----------------------------|-------------------------|
| HIV negative    |              |              |                            |                         |
| IL-17A concentration (pg/ml) | 0 | 2 | 4 | 6 |
| Groups          | Normotensive | Preeclamptic | Early-onset preeclamptic | Late-onset preeclamptic |
| HIV negative    |              |              |                            |                         |
compared to the PE (mean = 6.775 pg/ml; 95% CI: 8.466–4.884). There was also a statistical difference between N and EOPE (Mann–Whitney U = 46.00; P = 0.0029) Figure 6. There was a decrease in the concentration of IL-17A in the N group (mean = 4.208 pg/ml; 95% CI: 4.705–3.711) compared to the EOPE (mean = 6.675 pg/ml; 95% CI: 8.466–4.884). However, there was no statistical significance in the concentration of IL-17A between the N and LOPE (Mann–Whitney U = 24.00; P = 0.6915) groups.

There was no statistical significance in the concentration of IL-17A between EOPE and LOPE (Mann–Whitney U = 13.00; P = 0.4633) Figure 6.

5. Discussion

Interleukin 17 (IL-17), also known as (IL-17A), is a major, strongly proinflammatory cytokine produced by Th17 helper cells [26]. This cytokine has potent proinflammatory properties, which have been associated with the development of inflammatory processes, acute immunological graft rejection, and autoimmune diseases such as PE and HIV/AIDS.

5.1. Based on Pregnancy Type. In our study, we have evaluated the serum concentration levels of IL-17A based on pregnancy type (N vs. PE), gestational age (N vs. EOPE and N vs. LOPE), HIV status (negative vs. positive), and duration of HAART (acute vs. chronic) in Black South African women.

We demonstrated a significant increase in serum levels of IL-17A in preeclamptics compared to normotensives (P < 0.0014) Figure 1. Our study is in accordance with those reporting increased levels of IL-17A in pregnancies complicated by miscarriage, preterm birth, and PE compared to normotensive pregnancies [21, 27–31] implicating the role of this cytokine in the pathophysiology of PE. Interestingly, IL-17A has also been incriminated in causing placental oxidative stress then serves as a stimulus to modulate the renin angiotensin system (particularly AT1-AAs) thus leading to PE development [21]. Similarly, Yang et al. reported
increased expression levels of IL-17A in PE placentas and serum compared to normotensives [32]. Additionally, Mlovarec et al. also found increased circulating interleukin 17 levels in preeclampsia compared to healthy nonpregnant and pregnant normotensive women [29]. More interestingly, a study conducted by Barnie et al. in Chinese women showed increased plasma levels of IL-17A in preeclampsia compared to normotensives; they concluded that increased levels of IL7A in PE women may be produced by innate lymphoid cells 3 (ILC3). Innate lymphoid cells are a recently identified lymphocyte population (gastrointestinal tract cells known to produce cytokines such as IL-17A and/or IL-22) rather than Th17 cells, since they noted no significant difference in Th17 cells in PE women compared to normotensive women [33, 34]. Similarly, another study done by Cao et al. in the Chinese population found increased serum levels of IL-17A in PE compared to normotensive women; however, they associated their finding with Th17 cell activity [35]. Although the majority of these studies have been conducted in Chinese population, more studies are needed in the Black South African population in order to validate our findings.

Data on the levels of IL-17A based on pregnancy type (normotensive vs. PE) are discrepant; IL-17 has been suggested to play a role in maintaining pregnancy by inducing secretion of progesterone and increasing invasiveness of placental cells [36, 37]. Moreover, IL-17 receptor has been reported to be expressed on extravillous trophoblasts to allow successful invasion of spiral arteries [36]. Surprisingly, some studies have reported no significant difference in the levels of IL-17A between normotensive and preeclamptic pregnancies [38, 39]. Therefore, more studies are still needed in order to understand how this cytokine is regulated based on the pregnancy type.

5.2 Based on Gestational Age. We observed a significant increase in serum levels of IL-17A in EOPE compared to N (P < 0.013) Figure 2. The serum levels of IL-17A were also significantly higher in LOPE compared to N (P < 0.0063) Figure 2. We observed no significant difference in serum levels between EOPE and LOPE. Our findings suggested that decreased levels of IL-17A in normotensives might be strongly associated with the development of LOPE since we noticed a higher significant increase in LOPE compared to normotensives. Yang et al. reported that IL-17 have a positive association with the formation of proteinuria during late-onset PE; therefore, we speculated that this might be the
reason why we observed a higher significance in LOPE when compared to normotensives [32].

5.3. Based in HIV Status. Th17 cells have been implicated in host defence against a variety of pathogens and are involved in the pathogenesis of autoimmune diseases. Recently, Th17 cells were shown to be reduced during HIV infection in humans and SIV infection in nonhuman primates [40].

Based on HIV status, we observed no significant difference in serum levels of IL-17A between HIV negative N vs. PE, N vs. EOPE, N vs. LOPE, and EOPE vs. LOPE Figure 3. However, we observed a significant difference in the levels of IL-17A in HIV-positive N vs. PE \( (P < 0.0114) \) and significant difference between N and EOPE \( (P < 0.0071) \) Figure 4. The levels of IL-17A were higher in PE compared to normotensives and significantly higher in EOPE compared to normotensives. These findings suggest that in the presence of HIV infection, IL-17A is involved in the pathophysiology of EOPE; however, the mechanism is unknown. To the best of our knowledge, no studies have reported on IL-17A based on gestational age. Normally, both pregnancy and HIV infection are marked by an increase in anti-inflammatory response. However, upon HAART administration, proinflammatory cytokine response is activated [13]. IL-17A is a proinflammatory cytokine, and proinflammatory response is known to induce the development of PE [11]. Studies have reported that administration of HAART in pregnant women predisposes them to PE development [41, 42]. Therefore, we speculated that increased levels on IL-17A in EOPE were due to chronic HAART exposure. We therefore evaluated IL-17A based on the duration of HAART.

5.4. Based on HAART Duration. Studies have reported that HIV-infected women have higher risk of PE development than HIV-naïve women [14, 43]. Both HIV and PE are immune conditions, and several inflammatory cytokines play
a role in the progression of these disorders. It is known that during the progression of HIV infection, Th2 response is activated; however, this is counteracted by the use of HAART. During the pathogenesis of PE, there is an increase in proinflammatory cytokines.

Several studies have documented that there is a decline in the levels of IL-17A in HIV-infected individuals [23, 44, 45]; however, upon HAART exposure, the levels of IL-17A become restored. Based on the duration of HAART, we found no significant difference in the serum levels of IL-17A between pregnancy type and gestational age in HAART-acute women Figure 5. This is due to the fact that during the early stages of HIV infection, the levels of IL-17A in HAART-naïve women are almost the same to those of HIV-negative individuals.

Interestingly, we found a significant increase in the serum levels of IL-17A in HAART-chronic women between N and PE (P < 0.0062) and between N and EOPE (P < 0.0029) Figure 6. The levels of IL-17A in PE were higher in PE compared to normotensives and in EOPE compared to normotensives. However, we noticed no significant difference between N and LOPE and between EOPE and LOPE. During the first trimester (placentation), Th17 cells play a role in promoting proliferation of trophoblast cells by secreting IL-17A [22]. Therefore, it is possible that chronic HAART exposure contributes to exaggerative secretion of IL-17A at this stage thus leading to the development of EOPE.

5.5. Study Limitations. CD4 counts were not available for all women as it is not a standard of practice in the public health institutions in SA; hence, the levels of IL-17A in our study could not be correlated with severity of HIV infection. Our findings are preliminary and limited by a small sample size. A larger cohort will enable further research. Further, the role of IL-17A in normotensive versus preeclamptic pregnancies needs further investigation, and peripheral expression of IL-17A needs to be collated with measures in the placenta. This study was restricted to SA Black women; thus, our findings may not necessarily apply to other ethnic groups.

6. Conclusion

Our findings suggested that IL-17A play a role in the pathophysiology of preeclampsia and that in the presence of HIV infection, chronic HAART exposure is associated with increased levels of IL-17A which might be associated with the pathophysiology of EOPE. The level of IL-17A can be used as a predictive risk indicator in HIV-associated PE.

7. Strengths

Previous studies have mainly focused on the role of IL-17A based on pregnancy type (N vs. PE) or HIV status (positive vs. negative). To our knowledge, this is the first study to report the expression of IL-17A in Black South African women based on pregnancy type, gestational age, HIV status, and duration of HAART.

8. Future Studies

More studies should be done on the role of IL-17A based on pregnancy type, gestational age, HIV status, and duration of HAART in different ethnic groups in order to see how this cytokine is regulated in other ethnic groups. Additionally, since serum levels of IL-17A cytokines were tested from peripheral circulating blood rather than fetomaternal interface, future studies should be done on serum from the fetomaternal interface since the primary source of the pathogenesis of preeclampsia arises from the placenta.

Abbreviations

- **BMI**: Body mass index
- **EOPE**: Early-onset preeclamptic
- **EOPE-**: HIV-negative early-onset preeclamptic
- **EOPE+**: HIV-positive early-onset preeclamptic
- **EOPE-acute**: Early-onset preeclamptic HAART-acute
- **EOPE-chronic**: Early-onset preeclamptic HAART-chronic
- **HAART**: Highly active antiretroviral therapy
- **HELLP syndrome**: Haemolysis, elevated liver enzymes, low platelet count syndrome
- **HIV**: Human immune deficiency virus
- **IFN-γ**: Interferon gamma
- **IL-1β**: Interleukin 1-beta
- **IL-2**: Interleukin 2
- **IL-6**: Interleukin 6
- **IL-8**: Interleukin 8
- **IL-12**: Interleukin 12
- **IL-17A**: Interleukin 17A
- **LOPE**: Late-onset preeclamptic
- **LOPE-**: HIV-negative late-onset preeclamptic
- **LOPE+**: HIV-positive late-onset preeclamptic
- **LOPE-acute**: HAART-acute late-onset preeclamptic
- **LOPE-chronic**: HIV-positive (HAART-chronic) late-onset preeclamptic
- **N**: Normotensive
- **N-**: HIV-negative normotensive
- **N-acute**: HAART-acute normotensive
- **N-chronic**: HAART-chronic normotensive
- **NHLS**: National Health Laboratory Services
- **PE**: Preeclampsia
- **PE-**: HIV-negative preeclamptic
- **Th1**: Proinflammatory cytokines
- **Th2**: Anti-inflammatory cytokines
- **TNF-α**: Tumor necrotic alpha.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Additional Points

**Clinical Significance.** Regardless of HIV status, IL-17A is elevated in normotensives compared to women with PE,
highlighting its role in normal pregnancy maintenance. The upregulation of IL-17A in HIV-positive PE women may be attributed to prolonged HAART exposure, rather than to PE aetiology.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors wish to thank Mrs. Semone Thakoordeen-Reddy and Ms. Louansha Nandl. This study was funded by UKZN College of Health Sciences and NRF grant number: 113138.

References

[1] Hypertension, Gestational, “Preeclampsia. ACOG Practice Bulletin No. 202. American College of Obstetricians and Gynecologists,” Obstetrics and Gynecology, vol. 133, no. 1, pp. e1–e25, 2019.

[2] P. Gathiram and J. Moodley, “Pre-eclampsia: its pathogenesis and pathophysiology,” Cardiovascular Journal of Africa, vol. 27, no. 2, pp. 71–78, 2016.

[3] T. Chaiworapongsa, P. Chaemsathong, L. Yeo, and R. Romero, “Pre-eclampsia part 1: current understanding of its pathophysiology,” Nature Reviews Nephrology, vol. 10, no. 8, pp. 466–480, 2014.

[4] A. Nääv, L. Erlandsson, J. Axelsson et al., “A1M ameliorates preeclampsia-like symptoms in placenta and kidney induced by cell-free fetal hemoglobin in rabbit,” PLoS One, vol. 10, no. 5, article e0125499, 2015.

[5] C. H. Backes, K. Markham, P. Moorehead, L. Cordero, C. A. Nankervis, and P. J. Giannone, “Maternal preeclampsia and neonatal outcomes,” Journal of Pregnancy, vol. 2011, 7 pages, 2011.

[6] WHO, AIDS leading cause of death globally in women of reproductive age, WHO Press, Geneva, 2009.

[7] D. C. Cornelius, “Preeclampsia: from inflammation to immunoregulation,” Clinical Medicine Insights: Blood Disorders, vol. 11, article 1179545X17SS2325, 2018.

[8] Y. Ma, Y. Ye, J. Zhang, C.-C. Ruan, and P.-J. Gao, “Immune imbalance is associated with the development of preeclampsia,” Medicine, vol. 98, no. 14, article e15080, 2019.

[9] A. C. Eddy, H. Chapman, F. Mahdi, E. M. George, and G. L. Bidwell III, “A novel anti-inflammatory agent for the management of preeclampsia,” The FASEB Journal, vol. 32, Supplement 1, p. 911.3, 2018.

[10] H. Kobayashi, M. Ichikawa, J. Akasaka, T. Tsunami, and T. Sado, “Immune-related pathophysiological causes relevant to a subset of patients with preeclampsia (Review),” World Academy of Sciences Journal, vol. 1, no. 2, pp. 59–66, 2019.

[11] N. R. Maharaj, A. Phulukdaree, S. Nagiah, P. Ramkaran, C. Tiloke, and A. A. Chuturgoon, “Pro-inflammatory cytokine levels in HIV infected and uninfected pregnant women with and without preeclampsia,” PLoS One, vol. 12, no. 1, article e0170063, 2017.

[12] S. Fiore, M.-L. Newell, D. Trabattoni et al., “Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women,” Journal of Reproductive Immunology, vol. 70, no. 1–2, pp. 143–150, 2006.

[13] W. N. Phoswa, T. Naicker, V. Ramsuran, and J. Moodley, “Preeclampsia: the role of highly active antiretroviral therapy and immune markers,” Inflammation Research, vol. 68, no. 1, pp. 47–57, 2019.

[14] H. M. Sebitloane, J. Moodley, and B. Sartorius, “Associations between HIV, highly active anti-retroviral therapy, and hypertensive disorders of pregnancy among maternal deaths in South Africa 2011–2013,” International Journal of Gynecology & Obstetrics, vol. 136, no. 2, pp. 195–199, 2017.

[15] M. Sansone, I. Sarno, G. Saccone et al., “Risk of preeclampsia in human immunodeficiency virus-infected pregnant women,” Obstetrics & Gynecology, vol. 127, no. 6, pp. 1027–1032, 2016.

[16] A. Liu, H. Wang, and X. Gao, “A correlation analysis of Th1/Th2 cells in preeclampsia patients,” International Journal of Clinical and Experimental Medicine, vol. 12, no. 11, pp. 12868–12873, 2019.

[17] T. Naicker, W. N. Phoswa, O. A. Onyangunga, P. Gathiram, and J. Moodley, “Angiogenesis, lymphangiogenesis, and the immune response in South African preeclamptic women receiving HAART,” International Journal of Molecular Sciences, vol. 20, no. 15, p. 3728, 2019.

[18] S. Rana, E. Lemoine, J. P. Granger, and S. A. Karumanchi, “Preeclampsia,” Circulation Research, vol. 124, no. 7, pp. 1094–1112, 2019.

[19] D. Darmochwal-Kolarz, M. Michalak, B. Kolarz et al., “The role of interleukin-17, interleukin-23, and transforming growth factor-β in pregnancy complicated by placental insufficiency,” BioMed Research International, 2017, Article ID 6904325, 5 pages, 2017.

[20] A. A. el Shahaway, R. R. A. Elhady, A. A. Abdelrhman, and S. Yahia, “Role of maternal serum interleukin 17 in preeclampsia: diagnosis and prognosis,” Journal of Inflammation Research, vol. 12, pp. 175–180, 2019.

[21] P. Dhillion, K. Wallace, F. Herse et al., “IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy,” American Journal of Physiology Regulatory, Integrative and Comparative Physiology, vol. 303, no. 4, pp. R353–R358, 2012.

[22] H.-X. Wu, L.-P. Jin, B. Xu, S.-S. Liang, and D.-J. Li, “Decidual stromal cells recruit Th17 cells into decidua to promote proliferation and invasion of human trophoblast cells by secreting IL-17,” Cellular & Molecular Immunology, vol. 11, no. 3, pp. 253–262, 2014.

[23] N. R. Klatt and J. M. Brenchley, “Th17 cell dynamics in HIV infection,” Current Opinion in HIV and AIDS, vol. 5, no. 2, pp. 135–140, 2010.

[24] B. Landi, V. Bezeccheri, B. Guerra et al., “HIV infection in pregnancy and the risk of gestational hypertension and preeclampsia,” World Journal of Cardiovascular Diseases, vol. 4, no. 5, pp. 257–267, 2014.

[25] C. L. Townsend, P. A. Tookey, M.-L. Newell, and M. Cortina-Borja, “Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission,” Antiviral Therapy, vol. 15, no. 5, pp. 775–783, 2010.

[26] S. L. Gaffen, “Structure and signalling in the IL-17 receptor family,” Nature Reviews Immunology, vol. 9, no. 8, pp. 556–567, 2009.

[27] T. Poordast, F. S. Najib, R. Baharlou, A. Bijani, S. M. Alamdarloo, and A. Poordast, “Assessment of T helper 17-associated
cytokines in third trimester of pregnancy," *Iranian Journal of Immunology*, vol. 14, no. 2, pp. 172–179, 2017.

[28] D. Darmochwal-Kolarz, B. Kolarz, M. Kludka-Sternik, and J. Oleszcuk, "O73. The role of Th17/Treg imbalance in normal pregnancy and pre-eclampsia," *Pregnancy Hypertension*, vol. 5, no. 3, p. 227, 2015.

[29] A. Molvarec, I. Czegle, J. Szijarto, and J. Rigo Jr., "Increased circulating interleukin-17 levels in preeclampsia," *Journal of Reproductive Immunology*, vol. 112, pp. 53–57, 2015.

[30] D. Darmochwal-Kolarz, M. Kludka-Sternik, J. Tabarkiewicz et al., "The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia," *Journal of Reproductive Immunology*, vol. 93, no. 2, pp. 75–81, 2012.

[31] A. Nakashima, M. Ito, T. Shima, N. D. Bac, T. Hidaka, and S. Saito, "Accumulation of IL-17-positive cells in decidua of inevitable abortion cases," *American Journal of Reproductive Immunology*, vol. 64, no. 1, pp. 4–11, 2010.

[32] X. Yang, J. Zhang, and Y. Ding, "Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia," *Medicine*, vol. 96, no. 18, article e6509, 2017.

[33] P. A. Barnie, X. Lin, Y. Liu, H. Xu, and Z. Su, "IL-17 producing innate lymphoid cells 3 (ILC3) but not Th17 cells might be the potential danger factor for preeclampsia and other pregnancy associated diseases," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 9, pp. 11100–11107, 2015.

[34] H. Spits, D. Artis, M. Colonna et al., "Innate lymphoid cells – a proposal for uniform nomenclature," *Nature Reviews Immunology*, vol. 13, no. 2, pp. 145–149, 2013.

[35] W. Cao, X. Wang, T. Chen et al., "The expression of notch/notch ligand, IL-35, IL-17, and Th17/Treg in preeclampsia," *Disease Markers*, vol. 2015, 9 pages, 2015.

[36] X. Yang, J. Zhang, and Y. Ding, "Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia," *Medicine*, vol. 96, no. 18, article e6509, 2017.

[37] A. Molvarec, I. Czegle, J. Szijarto, and J. Rigo Jr., "Increased circulating interleukin-17 levels in preeclampsia," *Journal of Reproductive Immunology*, vol. 112, pp. 53–57, 2015.

[38] D. Darmochwal-Kolarz, M. Kludka-Sternik, J. Tabarkiewicz et al., "The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia," *Journal of Reproductive Immunology*, vol. 93, no. 2, pp. 75–81, 2012.

[39] A. Nakashima, M. Ito, T. Shima, N. D. Bac, T. Hidaka, and S. Saito, "Accumulation of IL-17-positive cells in decidua of inevitable abortion cases," *American Journal of Reproductive Immunology*, vol. 64, no. 1, pp. 4–11, 2010.

[40] X. Yang, J. Zhang, and Y. Ding, "Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia," *Medicine*, vol. 96, no. 18, article e6509, 2017.

[41] P. A. Barnie, X. Lin, Y. Liu, H. Xu, and Z. Su, "IL-17 producing innate lymphoid cells 3 (ILC3) but not Th17 cells might be the potential danger factor for preeclampsia and other pregnancy associated diseases," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 9, pp. 11100–11107, 2015.

[42] H. Spits, D. Artis, M. Colonna et al., "Innate lymphoid cells – a proposal for uniform nomenclature," *Nature Reviews Immunology*, vol. 13, no. 2, pp. 145–149, 2013.

[43] W. Cao, X. Wang, T. Chen et al., "The expression of notch/notch ligand, IL-35, IL-17, and Th17/Treg in preeclampsia," *Disease Markers*, vol. 2015, 9 pages, 2015.

[44] L. Campillo-Gimenez, M.-C. Cumont, M. Fay et al., "AIDS progression is associated with the emergence of IL-17–producing cells early after simian immunodeficiency virus infection," *The Journal of Immunology*, vol. 184, no. 2, pp. 984–992, 2010.

[45] H. M. al-Nafea, N. M. Hamdy, and N. M. Aref, "Evaluation of interleukin 17 level as a prognostic marker in active antiviral treated human immunodeficiency virus in Saudi patients," *American Journal of Biochemistry*, vol. 7, no. 2, pp. 13–22, 2017.